Monday, April 21st, 2025

Longfor Group Holdings Ltd: Promising Buy Opportunity with Strong Growth Targets

Date: September 30, 2024
Broker: CGS International Securities

Company Overview

Longfor Group Holdings Ltd is a property development company based in China. The company specializes in the development and management of residential and commercial properties.

Technical Analysis

Longfor Group Holdings Ltd is currently identified as a technical buy, indicating a favorable outlook for the stock based on market trends.

Key Price Levels:

  • Entry Prices: 13.72, 12.00, 8.50
  • Stop Loss: 7.60
  • Target Prices:
    • Target 1: 16.12
    • Target 2: 20.50
    • Target 3: 26.40
    • Target 4: 32.50

Trend Outlook

The stock’s technical indicators reflect a potential for significant upward movement, supported by the outlined target prices which suggest robust growth opportunities for investors.

Analyst Recommendation

Investors are encouraged to enter at the suggested entry prices while maintaining a stop loss at 7.60. The defined target prices provide a strategic framework for capturing profits as the stock is expected to appreciate in value.

SATSL$3.84, buy on pull back.

The chart of SATS SATSL$3.84, buy on pull back. more that 4% upside in short term. SATS reported a significant increase in net profit for 2Q FY25, growing by S\$47.5M (> 200% YoY) to...

Mynews Holdings: Strong Q4 Results Signal Positive Outlook for Malaysian Convenience Store Chain

Comprehensive Analysis of Mynews Holdings Comprehensive Analysis of Mynews Holdings Date: December 20, 2024 Broker: Maybank Investment Bank Berhad Introduction Maybank Investment Bank Berhad delivers an insightful overview of Mynews Holdings, providing a detailed...

CSPC Innovation Pharmaceutical Co Eyes Growth with Strategic Acquisition and Promising R&D Achievements

Date: October 18, 2024Broker: UOB Kay Hian Private Limited Company Overview CSPC Innovation Pharmaceutical Co is a producer of functional raw materials and health food, transforming into a leading drug innovator in China. The...